Praktické lékárenství – 3E/2021

www.praktickelekarenstvi.cz e34 AKTUÁLNÍ FARMAKOTERAPIE Farmakokinetické a farmakodynamické lékové interakce antiepileptik PRAKTICKÉ LÉKÁRENSTVÍ ce mezi antiepileptiky. Klin Farmakol Farm 2016; 30(4): 19–23. 9. Zaccara G, Perucca E. Interactions between antiepileptic drugs, and between antiepi- leptic drugs and other drugs. Epileptic Disord 2014; 16 (4): 409–432. 10. Bauer LA. Interference of oral phenytoin absorption by continuous nasogastric feedings. Neurology 1982; 32: 570–572. 11. Kitada N, Nishiyama Y, Watari M, Kuroda K, Kubo S, Nakata H, Ohnishi N, Yokoyama T. Reductions in plasma phenytoin concentrations during nasogastric enteral feeding in the patients with cerebral infarction. Jpn J TDM 2002; 3: 282–287. 12. Urashima Y, Urashima K, Ohnishi M, Matsushita K, Suzuki K, Kurachi K, Nishihara M, Kat- sumata T, Myotoku M, Ikeda K, Hirotani Y. Interaction between phenytoin and enteral nut- rients and its influence on gastrointestinal absorption. Pharmazie 2019; 74: 559–562. 13. Nagai K, Omotani S, Shibano M, Kobayashi A, Ito A, Nishimura I, Hatsuda Y, Mukai J, Tera- machi H, Myotoku M. Effects of semi‑solidification of enteral nutrients on the pharmacokine- tic behavior of orally administered carbamazepine in rats. Int J Med Sci. 2019; 16(9): 1283–1286. 14. VandenBerg A, Broadway J. Enteral administration of protein supplement and valproa- te: A potential pharmacokinetic interaction. Ment Health Clin [Internet]. 2017; 7(1): 10–12. 15. Patsalos PN, Froscher W, Pisani F, van Rijn CM. The Importance of Drug Interactions in Epilepsy Therapy. Epilepsia 2002; 43(4): 365–385. 16. Landmark CJ, Johannessen SI, Patsalos PN. Therapeutic drug monitoring of antiepilep- tic drugs: current status and future prospects. Expert Opin Drug Metab Toxicol. 2020 Mar; 16(3): 227–238. 17. Klomp SD, Manson ML, Guchelaar HJ, Swen JJ. Phenoconversion of Cytochrome P450 Metabolism: A Systematic Review. J Clin Med. 2020 Sep 7; 9(9): 2890. 18. Verrotti A, Lattanzi S, Brigo F, Zaccara G. Pharmacodynamic interactions of antiepileptic drugs: From bench to clinical practice. Epilepsy Behav. 2020 Mar; 104(Pt A): 106939. 19. Morano A, Fanella M, Albini M, Cifelli P, Palma E, Giallonardo AT, Di Bonaventura C. Ca- nnabinoids in the Treatment of Epilepsy: Current Status and Future Prospects. Neuropsy- chiatr Dis Treat. 2020 Feb 7; 16: 381–396. 20. Spina E, Pisani F, de Leon J. Clinically significant pharmacokinetic drug interactions of antiepileptic drugs with new antidepressants and new antipsychotics. Pharmacol Res. 2016 Apr; 106: 72–86. 21. Hakkola J, Hukkanen J, Turpeinen M, Pelkonen O. Inhibition and induction of CYP en- zymes in humans: an update. Archives of Toxicology 2020; 94: 3671–3722. 22. Stingl JC, Bartels H, Viviani R, Lehmanna ML, Brockmöller J. Relevance of UDP­ ‑glucuronosyltransferase polymorphisms for drug dosing: A quantitative systematic re- view. Pharmacol Ther. 2014 Jan; 141(1): 92–116. 23. Kacířová I, Grundmann M. Terapeutické monitorování hladin antiepileptik II. – „nová“ antiepileptika, speciální skupiny pacientů. Klin Farmakol Farm 2016; 30(2): 16–22.